Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.

Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.

Cell Rep. 2019 Jan 8;26(2):469-482.e5. doi: 10.1016/j.celrep.2018.12.043.

2.

NOTUM inhibition increases endocortical bone formation and bone strength.

Brommage R, Liu J, Vogel P, Mseeh F, Thompson AY, Potter DG, Shadoan MK, Hansen GM, Jeter-Jones S, Cui J, Bright D, Bardenhagen JP, Doree DD, Movérare-Skrtic S, Nilsson KH, Henning P, Lerner UH, Ohlsson C, Sands AT, Tarver JE, Powell DR, Zambrowicz B, Liu Q.

Bone Res. 2019 Jan 8;7:2. doi: 10.1038/s41413-018-0038-3. eCollection 2019.

3.

LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.

Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2017 Jul;362(1):85-97. doi: 10.1124/jpet.117.240820. Epub 2017 Apr 25.

PMID:
28442582
4.

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.

Goodwin NC, Ding ZM, Harrison BA, Strobel ED, Harris AL, Smith M, Thompson AY, Xiong W, Mseeh F, Bruce DJ, Diaz D, Gopinathan S, Li L, O'Neill E, Thiel M, Wilson AG, Carson KG, Powell DR, Rawlins DB.

J Med Chem. 2017 Jan 26;60(2):710-721. doi: 10.1021/acs.jmedchem.6b01541. Epub 2017 Jan 17.

PMID:
28045524
5.

Identification of potent and selective MTH1 inhibitors.

Petrocchi A, Leo E, Reyna NJ, Hamilton MM, Shi X, Parker CA, Mseeh F, Bardenhagen JP, Leonard P, Cross JB, Huang S, Jiang Y, Cardozo M, Draetta G, Marszalek JR, Toniatti C, Jones P, Lewis RT.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1503-1507. doi: 10.1016/j.bmcl.2016.02.026. Epub 2016 Feb 11.

PMID:
26898335
6.

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.

Powell DR, Smith MG, Doree DD, Harris AL, Xiong WW, Mseeh F, Wilson A, Gopinathan S, Diaz D, Goodwin NC, Harrison B, Strobel E, Rawlins DB, Carson K, Zambrowicz B, Ding ZM.

Pharmacol Res Perspect. 2015 Mar;3(2):e00129. doi: 10.1002/prp2.129. Epub 2015 Mar 31.

7.

Effect of LX4211 on glucose homeostasis and body composition in preclinical models.

Powell DR, DaCosta CM, Smith M, Doree D, Harris A, Buhring L, Heydorn W, Nouraldeen A, Xiong W, Yalamanchili P, Mseeh F, Wilson A, Shadoan M, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2014 Aug;350(2):232-42. doi: 10.1124/jpet.114.214304. Epub 2014 May 21.

PMID:
24849925
8.

Identification of small molecules that selectively inhibit diacylglycerol lipase-α activity.

Appiah KK, Blat Y, Robertson BJ, Pearce BC, Pedicord DL, Gentles RG, Yu XC, Mseeh F, Nguyen N, Swaffield JC, Harden DG, Westphal RS, Banks MN, O'Connell JC.

J Biomol Screen. 2014 Apr;19(4):595-605. doi: 10.1177/1087057113511111. Epub 2013 Nov 15.

PMID:
24241710
9.

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.

Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2013 May;345(2):250-9. doi: 10.1124/jpet.113.203364. Epub 2013 Mar 13.

PMID:
23487174
10.

Improved glycemic control in mice lacking Sglt1 and Sglt2.

Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B.

Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E117-30. doi: 10.1152/ajpendo.00439.2012. Epub 2012 Nov 13.

11.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR.

Clin Pharmacol Ther. 2012 Aug;92(2):158-69. doi: 10.1038/clpt.2012.58. Epub 2012 Jul 4.

12.

Lrp5 functions in bone to regulate bone mass.

Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA, Brommage R, Liu Q, Mseeh F, Powell DR, Yang QM, Zambrowicz B, Gerrits H, Gossen JA, He X, Bader M, Williams BO, Warman ML, Robling AG.

Nat Med. 2011 Jun;17(6):684-91. doi: 10.1038/nm.2388. Epub 2011 May 22.

13.

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Goodwin NC, Mabon R, Harrison BA, Shadoan MK, Almstead ZY, Xie Y, Healy J, Buhring LM, DaCosta CM, Bardenhagen J, Mseeh F, Liu Q, Nouraldeen A, Wilson AG, Kimball SD, Powell DR, Rawlins DB.

J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.

PMID:
19785435
14.

Experimental determination and system level analysis of essential genes in Escherichia coli MG1655.

Gerdes SY, Scholle MD, Campbell JW, Balázsi G, Ravasz E, Daugherty MD, Somera AL, Kyrpides NC, Anderson I, Gelfand MS, Bhattacharya A, Kapatral V, D'Souza M, Baev MV, Grechkin Y, Mseeh F, Fonstein MY, Overbeek R, Barabási AL, Oltvai ZN, Osterman AL.

J Bacteriol. 2003 Oct;185(19):5673-84.

15.

Mutagenesis studies of the human MT2 melatonin receptor.

Gerdin MJ, Mseeh F, Dubocovich ML.

Biochem Pharmacol. 2003 Jul 15;66(2):315-20.

PMID:
12826274
16.

Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch.

Karthikeyan S, Zhou Q, Mseeh F, Grishin NV, Osterman AL, Zhang H.

Structure. 2003 Mar;11(3):265-73.

17.

Identification of cysteines involved in ligand binding to the human melatonin MT(2) receptor.

Mseeh F, Gerdin MJ, Dubocovich MI.

Eur J Pharmacol. 2002 Aug 2;449(1-2):29-38.

PMID:
12163103
18.

From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways.

Gerdes SY, Scholle MD, D'Souza M, Bernal A, Baev MV, Farrell M, Kurnasov OV, Daugherty MD, Mseeh F, Polanuyer BM, Campbell JW, Anantha S, Shatalin KY, Chowdhury SA, Fonstein MY, Osterman AL.

J Bacteriol. 2002 Aug;184(16):4555-72.

19.

Inactivation of platelet PDE2 by an affinity label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP.

Mseeh F, Colman RF, Colman RW.

Thromb Res. 2000 Jun 1;98(5):395-401. Erratum in: Thromb Res 2000 Nov 1;100(3):249.

PMID:
10828479

Supplemental Content

Support Center